Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyAetna inert gas rebreathing Coverage Policy Update…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0714

    Rebreathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt

    Customize your policy alerts

    Sign up for Aetna Policy 0714 alerts

    Get alerted when Policy 0714 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses use of inert (foreign) gas rebreathing techniques to measure cardiac output and to validate intra-cardiac shunts, and states Aetna's coverage stance for these procedures and related indications.

    Policy Summary
    PayerAetna
    PolicyRebreathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt
    Policy CodePolicy 0714
    Change TypeNo material change
    Effective DateSep 30, 2005
    Last ReviewSep 21, 2023
    Next Review DateAug 8, 2024
    Key ActionDo not submit prior authorization for inert gas rebreathing procedures considered experimental and investigational; document rationale and comparators if submitted for review or validation studies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3indications listed as experimental/investigational
    510(k)FDA clearance pathway noted for devices
    multiplepublished comparative studies cited
    NCapplicable state

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    42%mortality in PH cohort

    Coverage Criteria

    Experimental and Investigational

    The policy lists the following procedures as experimental and investigational because effectiveness has not been established:

    Experimental/Investigational Procedures: 1. Rebreathing of inert gas for the measurement of cardiac output. 2. Rebreathing of inert gas for the prediction of survival in persons with pulmonary hypertension. 3. Rebreathing of inert gas for the validation of intra-cardiac shunt.

    These three specific uses are designated experimental/investigational in the policy.

    This policy addresses the use of inert gas rebreathing (IGR) techniques for noninvasive measurement of cardiac output and for validation of intra-cardiac shunt. Aetna considers the following procedures experimental and investigational because their effectiveness has not been established: (1) rebreathing of inert gas for the measurement of cardiac output; (2) rebreathing of inert gas for prediction of survival in persons with pulmonary hypertension; and (3) rebreathing of inert gas for validation of intra-cardiac shunt.

    Accuracy of IGR can be limited in certain pulmonary conditions. Incomplete alveolar gas mixing and intrapulmonary shunting can cause underestimation of pulmonary blood flow, reducing the reliability of IGR measurements in patients with significant lung disease. Comparisons to reference methods are also affected by limitations of those methods (for example, thermodilution is less reliable with tricuspid regurgitation or low cardiac output, and indirect Fick depends on estimated oxygen consumption). These factors should be considered when interpreting IGR results and when selecting alternative or confirmatory CO measurement techniques.

    The policy explicitly classifies the listed inert gas rebreathing applications as experimental and investigational because current evidence does not establish their effectiveness. As a result, these procedures are not supported for routine clinical use for cardiac output measurement, prognostication in pulmonary hypertension, or intra-cardiac shunt validation.

    Clinical use considerations

    Evidence considerations and contextual guidance from cited studies

    General evidence context: IGR is a feasible, noninvasive method to measure cardiac output/pulmonary blood flow with validation against various reference methods in multiple studies, and is simple and low-cost to perform.

    Supported by studies including postural stress, PH cohorts, and device validations.

    Settings where IGR may be useful: Outpatient or community monitoring of pulmonary hypertension; assessment during postural changes (e.g., CMR postural stress protocols); and pre/post assessment in studies of ASD closure for shunt quantification.

    Authors suggest potential utility but emphasize need for multicenter validation and serial measurements.

    Limitations and situations requiring caution: Accuracy of IGR may be reduced in patients with significant lung disease (due to incomplete alveolar gas mixing and intrapulmonary shunting), in presence of tricuspid regurgitation or low cardiac output (which affect thermodilution comparisons), and many studies are single-center or small cohorts limiting generalizability.

    Explicit limitations described in PH and comparative studies.

    Coding and Device Authorization

    ICD-10 codes referenced as related/not coveredICD-10
    I27.0Pulmonary hypertension
    I27.20Pulmonary hypertension, unspecified
    I27.21
    I27.22
    I27.23
    I27.24
    I27.29
    Q21.0Congenital malformations of cardiac septa [intra cardiac shunt]
    Q21.1
    Q21.2
    1–10 of 14
    1/2
    CPT/HCPCS codes for re-breathingCPT | HCPCS
    No codes listed
    Device 510(k) Summariesmixed
    K051907FDA 510(k) summary for Innocor Noninvasive Cardiac Output Monitor
    K041450FDA 510(k) summary for NICO with MARS, Model 7300
    Pediatric body surface area / tidal volume feasibility notes
    Pediatric body surface area thresholdBody surface area (BSA) > 0.6 m2 is associated with acceptable accuracy for partial CO2 re-breathing methods in children.
    Tidal volume thresholdTidal volume > 300 mL is associated with better agreement between partial CO2 re-breathing and thermodilution measurements.
    Weight feasibility cutoffTechniques become unfeasible in patients weighing less than 15 kg.

    Provider Actions and Authorization Guidance

    Billing Rule

    Coding / Authorization

    Coding/Authorization note: No specific CPT or HCPCS codes are assigned to inert gas rebreathing (IGR) procedures in this policy. When billing, verify applicable procedure and diagnosis codes; note that ICD‑10 codes for pulmonary hypertension (I27.0, I27.20‑I27.29) and congenital cardiac septal defects (Q21.0‑Q21.9) are listed as related indications and may affect claim adjudication. Because IGR is classified as experimental/investigational for measurement of cardiac output and validation of intra‑cardiac shunt under this policy, payers may deny reimbursement for these procedures.

    • No specific CPT/HCPCS codes designated in this policy.
    • Related ICD‑10 codes called out: I27.0, I27.20‑I27.29 (pulmonary hypertension); Q21.0‑Q21.9 (congenital cardiac septa).
    • Procedures deemed experimental/investigational may be denied as not medically necessary.
    Prior Authorization

    Definitions

    Inert gas rebreathing — definition and method summary
    DefinitionInert gas rebreathing (foreign gas re-breathing) is a noninvasive technique using physiologically inert, blood‑soluble gases inhaled via a closed rebreathing system to measure cardiac output by analyzing gas concentration wash‑out or uptake curves.
    Method summary - gases usedCommonly used inert gases include acetylene, carbon dioxide and nitrous oxide.
    Method summary - procedureA small amount of inert gas is inhaled from a rebreathing bag while the patient breathes through a mouthpiece with the nose clipped; an analyzer measures the concentration curve to calculate wash‑out rate proportional to cardiac output.
    NICO / partial CO2 re-breathing — definition and brief accuracy note
    DefinitionNICO / partial CO2 re-breathing estimates cardiac output using the ratio of the change in end‑tidal CO2 partial pressure and CO2 elimination in response to a brief period of partial rebreathing.

    Background

    Measurement of cardiac output is an important component of cardiovascular assessment and management. Invasive thermodilution using a pulmonary artery catheter (PAC) has been the established reference method in many clinical settings. Noninvasive techniques such as inert gas rebreathing aim to estimate pulmonary blood flow and cardiac output by analyzing gas uptake or washout during a closed rebreathing maneuver; however, despite device clearances and published studies, IGR remains differentiated from the established thermodilution approach and, per this policy, is designated as experimental/investigational for the listed indications.

    Policy Summary
    PayerAetna
    PolicyRebreathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt
    Policy CodePolicy 0714
    Change TypeNo material change
    Effective DateSep 30, 2005
    Last ReviewSep 21, 2023
    Next Review DateAug 8, 2024
    Key ActionDo not submit prior authorization for inert gas rebreathing procedures considered experimental and investigational; document rationale and comparators if submitted for review or validation studies.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Device AuthorizationProvider Actions and Authorization GuidanceDefinitionsBackground
    Prognostic findings in pulmonary hypertension: Single-center data have shown IGR (e.g., Innocor) can have long-term prognostic value comparable to invasive cardiac output in PH, but other studies found pulmonary blood flow by IGR did not independently predict survival when accounting for DLCO, 6MWD and other measures; results are therefore mixed and further validation is needed.

    Mixed findings reported across studies; multicenter and serial-measure studies recommended.

    Device Clearance and Authorization

    Device clearance/authorization: Some IGR devices have received FDA 510(k) clearance (for example, the Innocor system and the NICO systems noted in device summaries). Clearance of a device does not, by itself, establish clinical utility for the indications in this policy. Providers should include device 510(k) documentation and model identifiers when submitting requests or appeals, and check payer-specific prior authorization requirements, as prior authorization may still be required despite device clearance.

    • FDA 510(k) summaries referenced: Innocor (K051907) and NICO with MARS, Model 7300 (K041450).
    • Include device model and 510(k) summary or equivalent documentation with authorization or appeal requests.
    • Confirm and obtain any payer prior authorization before performing IGR when coverage is uncertain.
    Denial Risk

    Denial Risk — Experimental/Investigational Classification

    Experimental/Investigational denial risk: IGR for measurement of cardiac output, prediction of survival in pulmonary hypertension, and validation of intra‑cardiac shunt is classified as experimental and investigational in this policy. As such, claims for these indications are at risk for medical necessity denial. Anticipate denials and prepare clinical justification and supporting evidence if pursuing coverage or appeal.

    • IGR for CO measurement, prognostication in pulmonary hypertension, and shunt validation is considered experimental/investigational.
    • Claims for these indications may be denied as not medically necessary.
    • When pursuing coverage, supply robust clinical evidence and rationale in prior authorization/appeal submissions.
    Note

    Accuracy Limitations and Interpretation

    Accuracy limitations that may affect interpretation: IGR may underestimate pulmonary blood flow and cardiac output in patients with pulmonary disease because of incomplete alveolar gas mixing and intrapulmonary shunting. Thermodilution and indirect Fick methods also have known limitations (e.g., tricuspid regurgitation, low output states, and assumptions about oxygen consumption). Be aware of these modality-specific limitations when interpreting results and documenting clinical decisions.

    • IGR underestimation risk in the presence of lung disease (incomplete gas mixing, intrapulmonary shunt).
    • Thermodilution and indirect Fick have limitations that can affect comparative accuracy (tricuspid regurgitation, low CO, O2 consumption estimation).
    • Document clinical context and known limitations when using CO measurements to guide care.
    Documentation Required

    Documentation for Shunt Validation Studies

    Documentation for shunt validation studies: For cases where IGR (often combined with thoracic bioimpedance) is used to estimate Qp/Qs, submit a clear comparison plan and supporting data. Provide the reference standard used (direct Fick, Doppler echocardiography, or catheterization), timing of measurements (pre/post intervention), device identifiers, and the method of simultaneous measurements. Include institutional review/ethics approval or trial registration when applicable.

    • State the reference standard for Qp/Qs (direct Fick, Doppler echo, or catheterization) and provide comparative protocol details.
    • Include device model, calibration/validation records, and timing of paired measurements (before/after closure or intervention).
    • Attach trial registration or institutional review documentation for prospective studies.
    Note

    Consider Alternative Methods in Lung Disease

    Consider alternative methods in lung disease: In patients with coexisting pulmonary disease or when intrapulmonary shunt is suspected, consider confirmatory or alternative cardiac output measurement methods (e.g., thermodilution via right heart catheterization, direct or indirect Fick method, Doppler echocardiography, or cardiac MRI) and document the rationale for method selection. When IGR is used in this context, document any measures taken to mitigate known accuracy issues and the clinical reason for choosing IGR.

    • Prefer alternative or confirmatory CO measurement methods when lung disease or intrapulmonary shunt may bias IGR results.
    • Document rationale for using IGR despite pulmonary disease and any mitigation steps taken.
    • When available, corroborate IGR findings with an accepted reference method.
    Accuracy noteAccuracy may be affected by ventilation conditions and clinical settings; studies showed similar accuracy to other techniques in some settings but underestimation or inappropriateness in others (e.g., post‑cardiopulmonary bypass, xenon anesthesia).
    Pediatric limitationPartial CO2 re‑breathing measurements had larger differences versus thermodilution in children with BSA ≤ 0.6 m2 and tidal volumes <300 mL.
    Qp/Qs — pulmonary-to-systemic output ratio for intracardiac shunt quantification
    DefinitionQp/Qs is the pulmonary-to-systemic output ratio used to quantify intracardiac shunt (shunt fraction).
    Clinical useQp/Qs is typically assessed by Doppler echocardiography, MRI, or catheterization and may be compared with noninvasive methods like IGR and thoracic bioimpedance in validation studies.
    Validation contextProspective studies plan to compare Qp/Qs measured by Doppler and direct Fick with ratios derived from IGR/TB before and after ASD closure.
    Innocor — device definition and FDA 510(k) identifier
    Device nameInnocor Noninvasive Cardiac Output Monitor (Innovision A/S).
    Regulatory identifierFDA 510(k) summary number: K051907.
    Intended useA commercially available inert gas rebreathing device cleared by FDA for noninvasive cardiac output measurement.